CD19 and neoplasm: Evaluation of cord-blood-derived fourth-generation anti-CD19 CAR-NK cells engineered for enhanced cytokine signal transduction achieved the virtually complete suppression of tumor growth in Raji (Burkitt-lymphoma-cell)-transplanted NSG mice, allowing up to 341 days of tumor-free survival, against the death of all control animals in under 1 month [124].